Semnur Pharmaceuticals and Denali Capital Acquisition Corp. Complete Business Combination; Semnur Shares Begin Trading on OTC Markets
Reuters
Sep 27
Semnur Pharmaceuticals and <a href="https://laohu8.com/S/DNQAF">Denali Capital Acquisition Corp.</a> Complete Business Combination; Semnur Shares Begin Trading on <a href="https://laohu8.com/S/OTCM">OTC Markets</a>
Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company, announced the closing of its previously announced business combination with Denali Capital Acquisition Corp. on September 22, 2025. Following the transaction, Semnur will continue to operate under its current name, and its common stock and warrants are expected to begin trading on the OTC Markets under the ticker symbols "SMNR" and "SMNRW," respectively, starting September 23, 2025. Scilex and its affiliates now own approximately 87.5% of Semnur's common stock. According to Semnur, the company intends to leverage the resources of the public capital markets to further develop and commercialize novel non-opioid pain therapies, including advancing its second Phase 3 clinical program for SP-102.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Capital Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-220455), on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.